Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

123 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
Boasberg P, Hamid O, O'Day S. Boasberg P, et al. Semin Oncol. 2010 Oct;37(5):440-9. doi: 10.1053/j.seminoncol.2010.09.004. Semin Oncol. 2010. PMID: 21074058 Review.
Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma.
O'Day SJ, Gammon G, Boasberg PD, Martin MA, Kristedja TS, Guo M, Stern S, Edwards S, Fournier P, Weisberg M, Cannon M, Fawzy NW, Johnson TD, Essner R, Foshag LJ, Morton DL. O'Day SJ, et al. J Clin Oncol. 1999 Sep;17(9):2752-61. doi: 10.1200/JCO.1999.17.9.2752. J Clin Oncol. 1999. PMID: 10561350
Interleukin-2 binds to ganglioside GD(1b).
Ravindranath MH, Gonzales A, Soh D, Nishimoto K, Tam WY, Bilchik A, Morton DL, O'Day S. Ravindranath MH, et al. Biochem Biophys Res Commun. 2001 May 4;283(2):369-73. doi: 10.1006/bbrc.2001.4797. Biochem Biophys Res Commun. 2001. PMID: 11327710
High-dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin-2 in patients with metastatic melanoma.
O'Day SJ, Boasberg PD, Kristedja TS, Martin M, Wang HJ, Fournier P, Cabot M, DeGregorio MW, Gammon G. O'Day SJ, et al. Cancer. 2001 Aug 1;92(3):609-19. doi: 10.1002/1097-0142(20010801)92:3<609::aid-cncr1361>;2-u. Cancer. 2001. PMID: 11505406 Clinical Trial.
Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma.
Agarwala SS, Glaspy J, O'Day SJ, Mitchell M, Gutheil J, Whitman E, Gonzalez R, Hersh E, Feun L, Belt R, Meyskens F, Hellstrand K, Wood D, Kirkwood JM, Gehlsen KR, Naredi P. Agarwala SS, et al. J Clin Oncol. 2002 Jan 1;20(1):125-33. doi: 10.1200/JCO.2002.20.1.125. J Clin Oncol. 2002. PMID: 11773161 Clinical Trial.
Metastatic melanoma: chemotherapy to biochemotherapy.
O'Day SJ, Kim CJ, Reintgen DS. O'Day SJ, et al. Cancer Control. 2002 Jan-Feb;9(1):31-8. doi: 10.1177/107327480200900105. Cancer Control. 2002. PMID: 11907464 Review.
An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis.
Jaeckle KA, Batchelor T, O'Day SJ, Phuphanich S, New P, Lesser G, Cohn A, Gilbert M, Aiken R, Heros D, Rogers L, Wong E, Fulton D, Gutheil JC, Baidas S, Kennedy JM, Mason W, Moots P, Russell C, Swinnen LJ, Howell SB. Jaeckle KA, et al. J Neurooncol. 2002 May;57(3):231-9. doi: 10.1023/a:1015752331041. J Neurooncol. 2002. PMID: 12125986 Clinical Trial.
Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine.
DiFronzo LA, Gupta RK, Essner R, Foshag LJ, O'Day SJ, Wanek LA, Stern SL, Morton DL. DiFronzo LA, et al. J Clin Oncol. 2002 Aug 1;20(15):3242-8. doi: 10.1200/JCO.2002.01.065. J Clin Oncol. 2002. PMID: 12149297
Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy.
O'Day SJ, Boasberg PD, Piro L, Kristedja TS, Wang HJ, Martin M, Deck R, Ames P, Shinn K, Kim H, Fournier P, Gammon G. O'Day SJ, et al. Clin Cancer Res. 2002 Sep;8(9):2775-81. Clin Cancer Res. 2002. PMID: 12231516 Clinical Trial.
Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine.
Hsueh EC, Essner R, Foshag LJ, Ollila DW, Gammon G, O'Day SJ, Boasberg PD, Stern SL, Ye X, Morton DL. Hsueh EC, et al. J Clin Oncol. 2002 Dec 1;20(23):4549-54. doi: 10.1200/JCO.2002.01.151. J Clin Oncol. 2002. PMID: 12454111 Clinical Trial.
123 results
Jump to page